The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals on Thursday. The drug, which is called suzetrigine ...

Protesters took to the streets of lower Manhattan to denounce and protest U.S. Immigration and Customs Enforcement (ICE) on ...

Vertex Pharmaceuticals rose Thursday night after ... Investors.com - Stocks Fade Late After Trump Tariff Threat; Duolingo, Square, Doximity In Focus The first-in-class drug, also known as ...

The Summerlin master-planned community offers more than 75 unique floor plans in 15 neighborhoods throughout eight distinct ...

When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.

At the recent 210mm Five-Year Ecological Innovation Conference, Dr. Zhang Yingbin, Head of Strategy, Product, and Marketing at Trinasolar, took the stage to highlight the transformative impact of the ...

The firm could possibly eye about $800 million for the second continuation fund. Others that have adopted this strategy include Vertex Holdings and technology investment firm Basil Partners, which was ...

and the "corners" curve is closer to the square's corners. Example 12: You can give a different size for each segment ("edges" method in yellow) or corner ("corners" method in red). The first vertex ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...